Nanoparticle Uptake in Human Corneal Cells: Size and Surface Effects

Study Background and Research Question

Ocular drug delivery remains a major challenge due to the eye's complex barrier systems, which severely restrict the bioavailability of topically administered agents. The corneal epithelium, although comprising just 10% of the total corneal thickness, is responsible for 90% of the barrier function, primarily due to its tightly packed cell layers and mucin-rich tear film. Traditional ophthalmic formulations—while easy to apply—often have low residence time and poor tissue penetration, limiting therapeutic efficacy and increasing risk of irritation or systemic side effects. Recent advances in nanoparticle-based delivery systems hold promise for overcoming these barriers by enhancing retention, tissue penetration, and controlled release. However, the mechanisms by which physicochemical properties of nanoparticles, such as size and surface chemistry, affect their interaction and uptake by corneal epithelial cells have not been fully elucidated. The reference study by Azadi and David directly addresses this knowledge gap, focusing on the uptake pathways of polymeric nanoparticles in a well-controlled in vitro corneal model (reference study).

Key Innovation from the Reference Study

This work represents a significant advance by systematically dissecting how nanoparticle size and surface chemistry govern their uptake mechanisms in human corneal epithelial cells (HCECs). Using monodisperse PLGA nanoparticles—surface-modified with either mucoadhesive (alginate, chitosan) or mucopenetrative (PEG) polymers—the study reveals that uptake is not uniform across formulations, but is strongly dictated by both particle size and surface charge. The use of specific endocytosis pathway inhibitors further clarifies the relative contribution of different cellular entry routes, providing a mechanistic basis for rational nanoparticle design in ocular drug delivery.

Methods and Experimental Design Insights

The authors synthesized PLGA nanoparticles using the emulsion-solvent evaporation method and controlled key parameters to generate spherical, monodisperse particles (PDI < 0.2) with size distributions from 100 to 250 nm and zeta potentials spanning −25 to +15 mV. Surface modifications included alginate and chitosan for mucoadhesion, and PEG for mucopenetration. Cytotoxicity was evaluated using the MTT assay, showing that all nanoparticle formulations maintained high cell viability (70–100%) at concentrations up to 100 μg/mL after 24 hours, indicating suitability for ophthalmic applications. Uptake studies employed an in vitro HCEC monolayer model, with simulated mucosal solution to mimic the in vivo ocular surface. To elucidate entry mechanisms, the study used pharmacological inhibitors specific for macropinocytosis, caveolae-mediated, clathrin-mediated, and phagocytic pathways, in combination with quantitative uptake assays.

Protocol Parameters

• Nanoparticle synthesis: Emulsion-solvent evaporation; target size 100–250 nm, PDI < 0.2.
• Surface modification: Use of alginate/chitosan for mucoadhesion; PEG for mucopenetration.
• HCEC model setup: Monolayer culture with simulated mucosal solution to approximate tear film conditions.
• Concentration range for cytotoxicity/uptake: Up to 100 μg/mL; 24 h incubation.
• Endocytic pathway analysis: Use of selective inhibitors—e.g., amiloride (macropinocytosis), nystatin (caveolae), chlorpromazine (clathrin), cytochalasin D (actin-dependent processes)—to parse pathway contributions.

Core Findings and Why They Matter

The study's principal findings are that energy-dependent endocytosis is the dominant mechanism for nanoparticle uptake by HCECs, with macropinocytosis and caveolae-mediated endocytosis accounting for the greatest proportion of internalization. Clathrin-mediated uptake also contributes, but to a lesser extent, while phagocytosis is negligible for the particle sizes and chemistries tested. Notably, 100 nm PLGA nanoparticles and PEG-modified variants (~150 nm) exhibited the highest cellular uptake, highlighting the importance of both small size and surface hydrophilicity in optimizing corneal delivery. These insights enable rational selection and engineering of nanoparticle properties to maximize ocular tissue penetration and retention, with direct translational relevance for designing therapies for anterior segment eye diseases (reference study).

Comparison with Existing Internal Articles

The findings align with and extend prior mechanistic studies of nanoparticle uptake, such as those summarized in "Nanoparticle Uptake in Corneal Cells: Size and Surface Effects", which also emphasize the centrality of particle size and surface chemistry in determining uptake efficiency. Other internal resources, including "Cytochalasin D: Actin Polymerization Inhibitor for Cell Assays", provide actionable workflows for using actin polymerization inhibitors like Cytochalasin D to dissect the roles of actin-dependent endocytic pathways—relevant since the present study used similar inhibitors to parse uptake mechanisms. Furthermore, "Cytochalasin D: Actin Polymerization Inhibitor for Advanced Cell Assays" details protocol-level recommendations for employing Cytochalasin D in nanoparticle uptake studies, underscoring its utility in confirming actin-dependent internalization routes in both oncology and ocular models.

Limitations and Transferability

While the in vitro HCEC model with simulated mucosal solution offers valuable mechanistic insight, it cannot fully replicate the in vivo complexities of the human ocular surface, including dynamic tear turnover, immune surveillance, and multi-layered corneal architecture. The study's focus on PLGA nanoparticles, though highly relevant, leaves open questions regarding the generalizability of findings to other nanoparticle platforms. Notably, pharmacological inhibitors (e.g., Cytochalasin D) can have off-target effects, and the absence of phagocytic uptake may not translate to all cell types or disease states. Further in vivo validation will be essential to confirm the predictive value of these in vitro findings for clinical translation.

Why this cross-domain matters, maturity, and limitations

By bridging fundamental cell biology tools—such as actin polymerization inhibitors—with advanced drug delivery research, the study showcases the power of mechanistic dissection in optimizing therapeutic strategies. As highlighted in internal and external literature, these approaches are mature for in vitro applications but require further adaptation for complex in vivo settings. The ability to target specific cellular uptake pathways has broad implications not only for ocular but also for other mucosal drug delivery challenges.

Research Support Resources

For researchers aiming to replicate or extend this work, the use of established actin polymerization inhibitors such as Cytochalasin D (SKU B6645) can be instrumental in selectively blocking actin-dependent endocytic pathways and mapping cellular uptake routes. According to the product information, this compound is a potent and selective inhibitor with validated application in cell cycle arrest, nanoparticle uptake studies, and cytoskeletal research. When designing experiments, it is advisable to use freshly prepared solutions and adhere to recommended concentrations (typically 0.2–0.5 μg/mL for cell culture). APExBIO offers Cytochalasin D as a reproducibly validated reagent suitable for advanced cellular assays in ocular and drug delivery research contexts.